MetaCap

Molecular Partners (MOLN) vs Voyager Therapeutics (VYGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 37.5% versus a loss of 63.4%. Over five years, VYGR leads with a -50.0% price change compared with -77.9% for MOLN. Molecular Partners is the larger company by market cap ($96.8 million vs $95.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MOLN-37.50%VYGR-63.40%
+31%-18%-68%
Nov 21, 20251 yearNov 20, 2026
MOLN-75.84%VYGR-53.50%
+319%+112%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MOLN versus VYGR key metrics
MetricMOLNVYGR
Share price$2.53$1.53
Market cap$96.80M$95.21M
1-day change-5.25%-4.97%
YTD return-42.07%-61.07%
1-year return-37.50%-63.40%
5-year return-77.87%-50.00%
EPS (TTM)$-1.68$-1.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$40.37M
Revenue growth (YoY)—-49.53%
Net income (latest FY)—$-119.72M
Operating margin—-326.56%
Net margin—-296.53%
52-week high$5.36$5.48
52-week low$2.52$1.48
Distance from 52-week high-52.89%-72.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+295.64%+829.41%
Average volume1.63K770.24K
Shares outstanding38.34M62.23M
Employees134141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed VYGR by 25.9 percentage points over the past year.

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Voyager Therapeutics

VYGR stock →

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

MOLN vs VYGR FAQ

Which is bigger, Molecular Partners or Voyager Therapeutics?

Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $95.21M for Voyager Therapeutics (VYGR).

Which stock has performed better over the past year, MOLN or VYGR?

MOLN returned -37.50% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.

Are Molecular Partners and Voyager Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons